KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade. Wang et al. identified PDIA6 as a KRAS-driven suppressor of PERK-dependent immunogenic cell death, fostering immune exclusion. PDIA6 inhibition restores CD8<sup>+</sup> T-cell immunity and sensitizes PDAC to immunotherapy, highlighting a targetable resistance mechanism in KRAS-mutant PDAC.
Authors
- Xiaoke Liu (ORCID: https://orcid.org/0000-0003-4782-0957)
- Liwei Zhao
- Guido Kroemer
- Oliver Kepp
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Hôpital Européen (FR)
Publication Details
- Journal
- OncoImmunology
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1080/2162402x.2026.2641424
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Association pour la Recherche sur le Cancer
- Institut National Du Cancer